Xavier Cheng-Hong Tsai

Xavier Cheng-Hong Tsai

Assistant Professor and Attending Physician at National Taiwan University Hospital

Selected talks or oral presentation

  • 2024 The International Congress of on Blood and Marrow Transplantation, Busan, Korea. Topic: CAR-T Therapy in Taiwan: Outcomes and Adverse Events from a National Registry Analysis
  • 2023 Invited speaker, Annual meeting of Asia Pacific Blood and Marrow Transplantation, Indonesia. Topic: Strategies for Augmenting Graft vs Tumor Effect post transplant
  • 2022 Invited speaker, Highlight of ASH international program, Asia-Pacific region. Topic: Measurable/minimal residual disease in patients with acute myeloid leukemia
  • 2019 The Asia-Pacific Blood and Marrow Transplantation & International Congress of on Blood and Marrow Transplantation, Busan, Korea. Topic: Impact of Delayed Complete Remission on Prognosis of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
  • 2019 Invited speaker, The Hematology society of Taiwan-European Hematology Association joint symposium, Taipei, Taiwan. Topics: The clinical implication of minimal residual disease monitoring by next-generation sequencing in acute myeloid leukemia
  • 2018 The International Congress of on Blood and Marrow Transplantation, Busan, Korea. Topic: Transplantation outcomes of haploidentical activities for hematological malignancies in Taiwan: Results from Taiwan Blood and Marrow Transplantation Registry (TBMTR)
  • 2016 The 78th Annual Meeting of Japanese Society of Hematology, Yokohama, Japan. Topic: Reduced Incidence of Interstitial Pneumonitis After Allogeneic Hematopoietic Stem Cell Transplantation Using a Modified Technique of Total Body Irradiation
  • 2015 The 77th Annual Meeting of Japanese Society of Hematology, Kanazawa, Japan. Topic: The Clinical and Prognostic Significance of Cohesin Mutations and Expressions in de novo Acute Myeloid Leukemia
  • 2014 The 5th International Hematologic Malignancies Conference: Bridging the Gap, Taipei, Taiwan. Topic: Higher Expression of Suppressor of Cytokine Signaling1 (SOCS1) in the Bone Marrow is an Unfavorable Prognostic Factor in Adult Patients with de novo Acute Myeloid Leukemia